Pascal Soriot (Getty)
AstraZeneca CEO Soriot plans new study to test that controversial 90% efficacy figure, waiting for US data before going to FDA
Pascal Soriot spent the long Thanksgiving weekend digging AstraZeneca out of a hole, promising to put an end to the questions around its interim Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.